The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
IPI-549-01-A phase 1/1b first in human study of IPI-549, a PI3K-γ inhibitor, as monotherapy and in combination with pembrolizumab in subjects with advanced solid tumors.
 
Anthony Tolcher
Employment - START
Leadership - Symphony Evolution
Consulting or Advisory Role - Akebia Therapeutics; ArQule; Asana Biosciences; Astex Pharmaceuticals; Bayer Schering Pharma; Bind Therapeutics; Blend Therapeutics; Celator; Dicerna; Endocyte; Genmab; Heron; Janssen; Johnson & Johnson; Johnson & Johnson; Mersana; Merus; Nanobiotix; Pharmacyclics; Pierre Fabre; Proximagen; Symphony Evolution; Upsher-Smith; Valent Technologies
Research Funding - AbbVie (Inst); ArQule (Inst); Asana Biosciences (Inst); Astex Pharmaceuticals (Inst); Bayer (Inst); Cerulean Pharma (Inst); Dicerna (Inst); Endocyte (Inst); Gilead Sciences (Inst); Infinity Pharmaceuticals (Inst); Macrogenics (Inst); Pfizer (Inst); TaiRx, Inc. (Inst)
 
David Hong
Research Funding - AstraZeneca (Inst); Eisai (Inst); Genentech (Inst); miRNA Therapeutics (Inst); Novartis (Inst); Pfizer (Inst)
 
Ryan Sullivan
Consulting or Advisory Role - Astex Pharmaceuticals; Biodesix; Novartis; Prometheus Laboratories
Other Relationship - Boehringer Ingelheim
 
James Mier
Research Funding - X4 Pharma
Patents, Royalties, Other Intellectual Property - AAceleron
 
Geoffrey Shapiro
Consulting or Advisory Role - Chugai Pharma; EMD Serono; G1 Therapeutics; Lilly; Takeda; Tesaro; Vertex
Research Funding - Aileron Therapeutics (Inst); AstraZeneca (Inst); Bayer (Inst); Cellceutix (Inst); Covidien (Inst); Cyclacel (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Immune Design (Inst); Lilly; Millennium (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); PTC Therapeutics (Inst); Puma Biotechnology (Inst); Sanofi (Inst); Tensha Therapeutics (Inst); Vertex (Inst)
 
Joseph Pearlberg
Employment - Infinity Pharmaceuticals
 
Les Brail
Employment - Infinity Pharmaceuticals
Stock and Other Ownership Interests - Infinity Pharmaceuticals; Lilly
Consulting or Advisory Role - Ignyta
 
Jahnavi Kharidia
Employment - Infinity Pharmaceuticals
 
Lixin Han
Employment - Infinity Pharmaceuticals
 
Claudio Dansky Ullmann
Employment - Infinity Pharmaceuticals
 
Howard Stern
Employment - Infinity Pharmaceuticals
Stock and Other Ownership Interests - Infinity Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Infinity Pharmaceuticals (Inst)
 
Jedd Wolchok
Stock and Other Ownership Interests - Potenza Therapeutics; Vesuvius Pharmaceuticals
Consulting or Advisory Role - Bristol-Myers Squibb; Genentech; Jounce Therapeutics; MedImmune; Merck; Polaris; Polynoma; ZIOPHARM Oncology
Research Funding - Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); MedImmune (Inst); Merck (Inst)
Patents, Royalties, Other Intellectual Property - I am a co-inventor on an issued patent for DNA vaccines for treatment of cancer in companion animals.
Travel, Accommodations, Expenses - Bristol-Myers Squibb